Distinguished in Acute Myeloid Leukemia (AML)

Cecile Pautas

Université Paris Est Créteil, 
Creteil, FR 
Distinguished in Acute Myeloid Leukemia (AML)
Université Paris Est Créteil, 
Creteil, FR 
OverviewLocationsClinical Research

Overview

Cecile Pautas practices in Creteil, France. Ms. Pautas is rated as a Distinguished expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Febrile Neutropenia, Agranulocytosis, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 64 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 38 articles and participated in 1 clinical trial in the study of Acute Myeloid Leukemia (AML).

Gender
Female

Locations

Université Paris Est Créteil, Creteil, France
Other Locations
Paris, France
Bordeaux, 33000, France
Toulouse, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Etude Exploratoire randomisée Comparant le Traitement Par Gemtuzumab Ozogamicin /Cytarabine au Traitement Standard Par Idarubicine/Cytarabinechez Les Sujets âgés de 60 à 80 Ans et présentant Une LAM et un Caryotype Non défavorable
Etude Exploratoire randomisée Comparant le Traitement Par Gemtuzumab Ozogamicin /Cytarabine au Traitement Standard Par Idarubicine/Cytarabinechez Les Sujets âgés de 60 à 80 Ans et présentant Une LAM et un Caryotype Non défavorable
Enrollment Status: Completed
Publish Date: February 02, 2024
Intervention Type: Drug
Study Drug: Gemtuzumab ozogamicin
Study Phase: Phase 2/Phase 3

64 Total Publications

Intermediate-Dose Cytarabine as Postinduction AML Therapy.
Intermediate-Dose Cytarabine as Postinduction AML Therapy.
Journal: NEJM evidence
Published: June 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Pautas's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile